Israel's Gamida Cell $16 million dollars in a fourth round led by Israel Healthcare Ventures. Elscint Biomedical Investment, Denali Ventures, Biomedical Investments and TEVA Pharmaceuticals also participated in the round. The money will be used to expand Gamida Cell's tissue regeneration product pipeline (including a cardiac regeneration product), the planned clinical testing of the company's flagship product StemEx, and the ongoing pre-clinical development of products.
- see the release on the venture round